BACKGROUND:Lipophagy is closely related to a variety of chronic metabolic diseases.Exercise can delay the pathological process of non-alcoholic fatty liver by regulating lipophagy,which has become one of the most popular studies in the field of sports medicine.OBJECTIVE:To summarize the regulatory role of lipophagy in non-alcoholic fatty liver disease and the mechanism of exercise-mediated lipophagy in non-alcoholic fatty liver disease.METHODS:CNKI,PubMed,and Web of Science databases were searched for relevant literature published from 1980 to 2025,using the search terms of"lipophagy,lipid metabolism,non-alcoholic fatty liver disease,aerobic exercise,resistance training,combined aerobic resistance exercise"in Chinese and English.Totally 98 documents were included according to inclusion and exclusion criteria.RESULTS AND CONCLUSION:(1)Lipophagy plays an important regulatory role in the prevention and treatment of non-alcoholic fatty liver disease.(2)Different types of exercises affect lipophagy:Aerobic exercise can play a beneficial role can regulate the expression of lipophagy related factors,enhance autophagy flow,improve lysosome biosynthesis and promote the decomposition of lipase.Resistance training can increase the expression of autophagy related factors in adipose tissue.Combined aerobic resistance exercise can increase fat oxidation rate and improve insulin sensitivity.(3)Exercise can treat non-alcoholic fatty liver disease by improving liver inflammation,insulin resistance,and liver function.(4)Exercise plays a key role in the prevention and treatment of non-alcoholic fatty liver by regulating lipophagy,reducing lipid accumulation,inhibiting steatosis,alleviating liver inflammation and fibrosis and improving insulin resistance.

BACKGROUND:Lipophagy is closely related to a variety of chronic metabolic diseases.Exercise can delay the pathological process of non-alcoholic fatty liver by regulating lipophagy,which has become one of the most popular studies in the field of sports medicine.OBJECTIVE:To summarize the regulatory role of lipophagy in non-alcoholic fatty liver disease and the mechanism of exercise-mediated lipophagy in non-alcoholic fatty liver disease.METHODS:CNKI,PubMed,and Web of Science databases were searched for relevant literature published from 1980 to 2025,using the search terms of"lipophagy,lipid metabolism,non-alcoholic fatty liver disease,aerobic exercise,resistance training,combined aerobic resistance exercise"in Chinese and English.Totally 98 documents were included according to inclusion and exclusion criteria.RESULTS AND CONCLUSION:(1)Lipophagy plays an important regulatory role in the prevention and treatment of non-alcoholic fatty liver disease.(2)Different types of exercises affect lipophagy:Aerobic exercise can play a beneficial role can regulate the expression of lipophagy related factors,enhance autophagy flow,improve lysosome biosynthesis and promote the decomposition of lipase.Resistance training can increase the expression of autophagy related factors in adipose tissue.Combined aerobic resistance exercise can increase fat oxidation rate and improve insulin sensitivity.(3)Exercise can treat non-alcoholic fatty liver disease by improving liver inflammation,insulin resistance,and liver function.(4)Exercise plays a key role in the prevention and treatment of non-alcoholic fatty liver by regulating lipophagy,reducing lipid accumulation,inhibiting steatosis,alleviating liver inflammation and fibrosis and improving insulin resistance.

Objective To investigate the effects of pantoprazole treatment in the prevention of gastric tumor bleeding in patients with unresectable gastric cancer. Methods This study was a prospective double-blind,randomized,placebo-controlled trial. From January 2014 to July 2015,patients with gastric tumor bleeding in Xuzhou Cancer Hospital were included in this study. 131 cases of unresectable gastric cancer were randomly divided into two groups. In the experimental group,66 cases were taken pantoprazole 40 mg,1 time / d,and 65 cases in the control group were given placebo 40 mg and 1 time/ d. The course of treatment was 8 weeks. The differences in tumor bleeding,blood transfusion requirements and overall survival time between the two groups were observed during the follow-up period. Results The median follow-up time was 6. 5 ( 3. 3, 13. 2 ) months. Seven cases ( 10. 61%) in pantoprazole group had tumor bleeding, and 13 ( 20%) in the placebo group. There was no significant difference in cumulative risk of tumor bleeding between the two groups (Gray's test: P = 0. 426) . However,in the first 5 months of follow-up,the cumulative incidence of tumor bleeding in pantoprazole group was 0,lower than that in placebo group (9. 23%) (6/ 65) (Gray's test: P = 0. 039). There was no significant difference in blood transfusion requirement and overall survival between the two groups. No drug-related adverse reactions and bleeding related deaths occurred during the follow-up period. Conclusion Pantoprazole can not significantly reduce tumor bleeding in patients with unresectable gastric cancer.